Stifel analyst Alex Thompson CFA maintains $RAPT Therapeutics (RAPT.US)$ with a hold rating, and maintains the target price at $2.
According to TipRanks data, the analyst has a success rate of 61.2% and a total average return of 17.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $RAPT Therapeutics (RAPT.US)$'s main analysts recently are as follows:
Rapt Therapeutics' recent discontinuation of the zelnecirnon program came after FDA feedback indicated challenges in disproving drug-induced liver failure. The lack of data disclosure and the uncertainty that surrounds the development of next-generation compounds, which may require additional capital, suggests Rapt now needs to demonstrate more to gain confidence.
The FDA's request for definitive evidence concerning liver SAEs was more conservative than expert expectations. Despite this, there is an observed efficacy signal from Phase 2b, which is promising for the next-generation compound. Further data is anticipated to evaluate the potential.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析师Alex Thompson CFA维持$RAPT Therapeutics (RAPT.US)$持有评级，维持目标价2美元。
根据TipRanks数据显示，该分析师近一年总胜率为61.2%，总平均回报率为17.5%。
此外，综合报道，$RAPT Therapeutics (RAPT.US)$近期主要分析师观点如下：
Rapt Therapeutics近期停止zelnecirnon项目是在FDA反馈指出难以证明药物引起的肝衰竭后做出的决定。数据披露的缺乏以及围绕下一代compound开发的不确定性，可能需要额外的资金，表明Rapt现在需要展示更多以获得信心。
FDA对肝脏SAE的明确证据要求比专家预期更保守。尽管如此，从Phase 20亿中观察到的疗效信号对下一代compound来说是一个好兆头。进一步的数据预计将用于评估其潜力。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
